There was a whole lot of hype after “Cannabis 2.0” happened in Canada in October 2019. It marked the second wave of recreational marijuana legalization in Canada. Cannabis 2.0 included cannabis derivatives products — namely cannabis-infused edibles, chocolates, beverages, vapes, and concentrates — while Cannabis 1.0 in October 2018 only legalized cannabis flowers and buds.

Image source: Getty Images.

While all marijuana companies ramped up production to grab the opportunities of this new market, Canopy Growth (NYSE:CGC) and Organigram Holdings (NASDAQ:OGI) have focused on providing the most innovative products to consumers. Surprisingly, while the COVID-19 pandemic has forced many to focus on conserving cash, these two are moving ahead with the launch of more derivatives products for this year.

A Deloitte research paper, “Nurturing New Growth,” stated that the potential for Cannabis 2.0 products could be huge — bringing in close to 2.7 billion Canadian dollars annually, with edibles worth CA$1.6 billion alone. The article stated: “Cannabis 2.0 will undoubtedly be a ‘slow burn’ at first, but as more products become available we’re confident it will catch fire and gain momentum. Cannabis 2.0 will position Canadian companies and talent for global growth — even as the US market gains…